Astra Aktiebolag

Aktiebolaget Astra

Astra Pharmaceutical Production Aktiebolag

Edib Jakupovic

Eric Nils Teneberg

Jan W Trofast

Eva A Trofast

Bengt Olof Sarnstrand

Magnus Leif Lindvall

Carl-Magnus Alexander Andersson

Bo-Goran Josefsson

Hangkan Sten Bergstrand

Lars-Erik Briggner

Hakan S Bergstrand

Jan U Stenhede

Katarina Bystrom

Katarina L Mansson

Roy T Sourander

Katarina U Bystrom

Jan Stenhede

Rolf P Svensson

A process for producing a pharmaceutical powder for inhalation comprising crystalline particles of an inhalation compound, comprising dissolving an inhalation compound in a solvent; and introducing the solution containing the inhalation compound in droplet form or as a jet stream into an anti-solvent which is miscible with the solvent and which is under agitation.

Process for the preparation of respirable particles

Forms of organic salts of N,N'-diacetylcystine

There are described finely divided particles of a pharmaceutical substance, wherein the substance when submitted to water vapor gives off heat of less than 1.2 Joules per gram, processes for their production and pharmaceutical formulations containing them.

Pharmaceutical formulation

New crystalline organic salts of N,N'-diacetyl cystine with immunomodulating effect, processes for their preparation, pharmaceutical compositions containing them and methods of their pharmacological use.

Method for the treatment of diseases due to defects the immune system

Organic salts of N,N'-diacetyl cystine

The present invention relates to a method for the synthesis of foscarnet, i.e. trisodium phosphonoformate hexahydrate, comprising the steps of adding sodium hydroxide to water, heating the aqueous sodium hydroxide solution to 50.degree. C., adding triethyl phosphonoformate to said solution at 50.degree. C., heating the reaction mixture to reflux for about 1 hour, cooling of the reaction mixture and filtering-off of the product.

Method for the synthesis of trisodium phosphonoformate hexahydrate

A process for providing water-soluble micronized pharmaceutically acceptable inhalable substances, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of the pharmaceutically acceptable substances. This process is carried out by the steps of reducing, if necessary, the residual water from the micronized substance by drying at an elevated temperature and/or vacuum; conditioning the dried, micronized pharmaceutically acceptable inhalable substances with a solvent; and eliminating residual solvent by storing under dry conditions as, e.g., in a vacuum or by purging with a dry, inert gas.

Process for conditioning of water-soluble substances

The present invention is directed to a process for preparing formoterol and related compounds and derivatives thereof and their pharmacologically and pharmaceutically acceptable fumarate salts and/or solvates. The present invention is also directed to certain formoterol related compounds per se.

Process for preparing formoterol and related compounds

A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives characterized in reaction of a corresponding 16,17-acetonide with an aldehyde or ketone in (a) hydrocarbon solvent wherein the solubility of the pregnane derivative is less than 1 mg/l or in a halogenated hydrocarbon solvent together with a hydrohalogen acid or an organic sulphonic acid as catalyst and in the presence of small grains of an insert material in the reaction medium or (b) a halogenated hydrocarbon solvent together with a hydrohalogen acid an organic sulphonic acid as catalyst and in the presence of an epimeric distribution modifier.

Method of controlling the epimeric distribution in the preparation of

Growing community of inventors

Nykvarn, Sweden

Edib Jakupovic